Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies

Jane C. Figueiredo; Fred R. Hirsch; Lawrence H. Kushi; Wendy N. Nembhard; James M. Crawford; Nicholas Mantis; Laurel Finster; Noah M. Merin; Akil Merchant; Karen L. Reckamp; Gil Y. Melmed; Jonathan Braun; Dermot Mcgovern; Samir Parekh; Douglas A. Corley; Namvar Zohoori; Benjamin C. Amick; Ruofei Du; Peter K. Gregersen; Betty Diamond; Emanuela Taioli; Carlos Sariol; Ana Espino; Daniela Weiskopf; Alba Gifoni; James Brien; William Hanege; Marc Lipsitch; David A. Zidar; Ann Scheck Mcalearney; Ania Wajnberg; Joshua Labaer; E. Yvonne Lewis; Raquel A. Binder; Ann M. Moormann; Catherine Forconi; Sarah Forrester; Jennifer Batista; John Schieffelin; Dongjoo Kim; Giulia Biancon; Jennifer Vanoudenhove; Stephanie Halene; Rong Fan; Dan H. Barouch; Galit Alter; Swetha Pinninti; Suresh B. Boppana; Sunil K. Pati; Misty Latting; Andrew H. Karaba; John Roback; Rafick Sekaly; Andrew Neish; Ahnalee M. Brincks; Douglas A. Granger; Amy B. Karger; Bharat Thyagarajan; Stefani N. Thomas; Sabra L. Klein; Andrea L. Cox; Todd Lucas; Debra Furr-Holden; Kent Key; Nicole Jones; Jens Wrammerr; Mehul Suthar; Serre Yu Wong; Natalie M. Bowman; Viviana Simon; Lynne D. Richardson; Russell Mcbride; Florian Krammer; Meenakshi Rana; Joshua Kennedy; Karl Boehme; Craig Forrest; Steve W. Granger; Christopher D. Heaney; Maria Knight Lapinski; Shannon Wallet; Ralph S. Baric; Luca Schifanella; Marcos Lopez; Soledad Fernandez; Eben Kenah; Ashish R. Panchal; William J. Britt; Iñaki Sanz; Madhav Dhodapkar; Rafi Ahmed; Luther A. Bartelt; Alena J. Markmann; Jessica T. Lin; Robert S. Hagan; Matthew C. Wolfgang; Jacek Skarbinski

doi:10.1093/ofid/ofac171

Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies

Jane C. Figueiredo, Fred R. Hirsch, Lawrence H. Kushi, Wendy N. Nembhard, James M. Crawford, Nicholas Mantis, Laurel Finster, Noah M. Merin, Akil Merchant, Karen L. Reckamp, Gil Y. Melmed, Jonathan Braun, Dermot Mcgovern, Samir Parekh, Douglas A. Corley, Namvar Zohoori, Benjamin C. Amick, Ruofei Du, Peter K. Gregersen, Betty DiamondEmanuela Taioli, Carlos Sariol, Ana Espino, Daniela Weiskopf, Alba Gifoni, James Brien, William Hanege, Marc Lipsitch, David A. Zidar, Ann Scheck Mcalearney, Ania Wajnberg, Joshua Labaer, E. Yvonne Lewis, Raquel A. Binder, Ann M. Moormann, Catherine Forconi, Sarah Forrester, Jennifer Batista, John Schieffelin, Dongjoo Kim, Giulia Biancon, Jennifer Vanoudenhove, Stephanie Halene, Rong Fan, Dan H. Barouch, Galit Alter, Swetha Pinninti, Suresh B. Boppana, Sunil K. Pati, Misty Latting, Andrew H. Karaba, John Roback, Rafick Sekaly, Andrew Neish, Ahnalee M. Brincks, Douglas A. Granger, Amy B. Karger, Bharat Thyagarajan, Stefani N. Thomas, Sabra L. Klein, Andrea L. Cox, Todd Lucas, Debra Furr-Holden, Kent Key, Nicole Jones, Jens Wrammerr, Mehul Suthar, Serre Yu Wong, Natalie M. Bowman, Viviana Simon, Lynne D. Richardson, Russell Mcbride, Florian Krammer, Meenakshi Rana, Joshua Kennedy, Karl Boehme, Craig Forrest, Steve W. Granger, Christopher D. Heaney, Maria Knight Lapinski, Shannon Wallet, Ralph S. Baric, Luca Schifanella, Marcos Lopez, Soledad Fernandez, Eben Kenah, Ashish R. Panchal, William J. Britt, Iñaki Sanz, Madhav Dhodapkar, Rafi Ahmed, Luther A. Bartelt, Alena J. Markmann, Jessica T. Lin, Robert S. Hagan, Matthew C. Wolfgang, Jacek Skarbinski

Molecular Sciences, School of (SMS)

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Background: Global efforts are needed to elucidate the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the underlying cause of coronavirus disease 2019 (COVID-19), including seroprevalence, risk factors, and long-Term sequelae, as well as immune responses after vaccination across populations and the social dimensions of prevention and treatment strategies. Methods: In the United States, the National Cancer Institute in partnership with the National Institute of Allergy and Infectious Diseases, established the SARS-CoV-2 Serological Sciences Network (SeroNet) as the nation's largest coordinated effort to study coronavirus disease 2019. The network comprises multidisciplinary researchers bridging gaps and fostering collaborations among immunologists, epidemiologists, virologists, clinicians and clinical laboratories, social and behavioral scientists, policymakers, data scientists, and community members. In total, 49 institutions form the SeroNet consortium to study individuals with cancer, autoimmune disease, inflammatory bowel diseases, cardiovascular diseases, human immunodeficiency virus, transplant recipients, as well as otherwise healthy pregnant women, children, college students, and high-risk occupational workers (including healthcare workers and first responders). Results: Several studies focus on underrepresented populations, including ethnic minorities and rural communities. To support integrative data analyses across SeroNet studies, efforts are underway to define common data elements for standardized serology measurements, cellular and molecular assays, self-reported data, treatment, and clinical outcomes. Conclusions: In this paper, we discuss the overarching framework for SeroNet epidemiology studies, critical research questions under investigation, and data accessibility for the worldwide scientific community. Lessons learned will help inform preparedness and responsiveness to future emerging diseases.

Original language	English (US)
Article number	ofac171
Journal	Open Forum Infectious Diseases
Volume	9
Issue number	6
DOIs	https://doi.org/10.1093/ofid/ofac171
State	Published - Jun 1 2022

Keywords

Cohort
Covid-19
Epidemiology
Sars-cov-2
Seronet
Serosurveillance

ASJC Scopus subject areas

Oncology
Infectious Diseases

Access to Document

10.1093/ofid/ofac171

Cite this

Figueiredo, J. C., Hirsch, F. R., Kushi, L. H., Nembhard, W. N., Crawford, J. M., Mantis, N., Finster, L., Merin, N. M., Merchant, A., Reckamp, K. L., Melmed, G. Y., Braun, J., Mcgovern, D., Parekh, S., Corley, D. A., Zohoori, N., Amick, B. C., Du, R., Gregersen, P. K., ... Skarbinski, J. (2022). Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. Open Forum Infectious Diseases, 9(6), Article ofac171. https://doi.org/10.1093/ofid/ofac171

Figueiredo, JC, Hirsch, FR, Kushi, LH, Nembhard, WN, Crawford, JM, Mantis, N, Finster, L, Merin, NM, Merchant, A, Reckamp, KL, Melmed, GY, Braun, J, Mcgovern, D, Parekh, S, Corley, DA, Zohoori, N, Amick, BC, Du, R, Gregersen, PK, Diamond, B, Taioli, E, Sariol, C, Espino, A, Weiskopf, D, Gifoni, A, Brien, J, Hanege, W, Lipsitch, M, Zidar, DA, Scheck Mcalearney, A, Wajnberg, A, Labaer, J, Yvonne Lewis, E, Binder, RA, Moormann, AM, Forconi, C, Forrester, S, Batista, J, Schieffelin, J, Kim, D, Biancon, G, Vanoudenhove, J, Halene, S, Fan, R, Barouch, DH, Alter, G, Pinninti, S, Boppana, SB, Pati, SK, Latting, M, Karaba, AH, Roback, J, Sekaly, R, Neish, A, Brincks, AM, Granger, DA, Karger, AB, Thyagarajan, B, Thomas, SN, Klein, SL, Cox, AL, Lucas, T, Furr-Holden, D, Key, K, Jones, N, Wrammerr, J, Suthar, M, Yu Wong, S, Bowman, NM, Simon, V, Richardson, LD, Mcbride, R, Krammer, F, Rana, M, Kennedy, J, Boehme, K, Forrest, C, Granger, SW, Heaney, CD, Knight Lapinski, M, Wallet, S, Baric, RS, Schifanella, L, Lopez, M, Fernandez, S, Kenah, E, Panchal, AR, Britt, WJ, Sanz, I, Dhodapkar, M, Ahmed, R, Bartelt, LA, Markmann, AJ, Lin, JT, Hagan, RS, Wolfgang, MC & Skarbinski, J 2022, 'Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies', Open Forum Infectious Diseases, vol. 9, no. 6, ofac171. https://doi.org/10.1093/ofid/ofac171

@article{3dc8ab1028e8407690b7e6308feb638c,

title = "Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies",

abstract = "Background: Global efforts are needed to elucidate the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the underlying cause of coronavirus disease 2019 (COVID-19), including seroprevalence, risk factors, and long-Term sequelae, as well as immune responses after vaccination across populations and the social dimensions of prevention and treatment strategies. Methods: In the United States, the National Cancer Institute in partnership with the National Institute of Allergy and Infectious Diseases, established the SARS-CoV-2 Serological Sciences Network (SeroNet) as the nation's largest coordinated effort to study coronavirus disease 2019. The network comprises multidisciplinary researchers bridging gaps and fostering collaborations among immunologists, epidemiologists, virologists, clinicians and clinical laboratories, social and behavioral scientists, policymakers, data scientists, and community members. In total, 49 institutions form the SeroNet consortium to study individuals with cancer, autoimmune disease, inflammatory bowel diseases, cardiovascular diseases, human immunodeficiency virus, transplant recipients, as well as otherwise healthy pregnant women, children, college students, and high-risk occupational workers (including healthcare workers and first responders). Results: Several studies focus on underrepresented populations, including ethnic minorities and rural communities. To support integrative data analyses across SeroNet studies, efforts are underway to define common data elements for standardized serology measurements, cellular and molecular assays, self-reported data, treatment, and clinical outcomes. Conclusions: In this paper, we discuss the overarching framework for SeroNet epidemiology studies, critical research questions under investigation, and data accessibility for the worldwide scientific community. Lessons learned will help inform preparedness and responsiveness to future emerging diseases.",

keywords = "Cohort, Covid-19, Epidemiology, Sars-cov-2, Seronet, Serosurveillance",

author = "Figueiredo, {Jane C.} and Hirsch, {Fred R.} and Kushi, {Lawrence H.} and Nembhard, {Wendy N.} and Crawford, {James M.} and Nicholas Mantis and Laurel Finster and Merin, {Noah M.} and Akil Merchant and Reckamp, {Karen L.} and Melmed, {Gil Y.} and Jonathan Braun and Dermot Mcgovern and Samir Parekh and Corley, {Douglas A.} and Namvar Zohoori and Amick, {Benjamin C.} and Ruofei Du and Gregersen, {Peter K.} and Betty Diamond and Emanuela Taioli and Carlos Sariol and Ana Espino and Daniela Weiskopf and Alba Gifoni and James Brien and William Hanege and Marc Lipsitch and Zidar, {David A.} and {Scheck Mcalearney}, Ann and Ania Wajnberg and Joshua Labaer and {Yvonne Lewis}, E. and Binder, {Raquel A.} and Moormann, {Ann M.} and Catherine Forconi and Sarah Forrester and Jennifer Batista and John Schieffelin and Dongjoo Kim and Giulia Biancon and Jennifer Vanoudenhove and Stephanie Halene and Rong Fan and Barouch, {Dan H.} and Galit Alter and Swetha Pinninti and Boppana, {Suresh B.} and Pati, {Sunil K.} and Misty Latting and Karaba, {Andrew H.} and John Roback and Rafick Sekaly and Andrew Neish and Brincks, {Ahnalee M.} and Granger, {Douglas A.} and Karger, {Amy B.} and Bharat Thyagarajan and Thomas, {Stefani N.} and Klein, {Sabra L.} and Cox, {Andrea L.} and Todd Lucas and Debra Furr-Holden and Kent Key and Nicole Jones and Jens Wrammerr and Mehul Suthar and {Yu Wong}, Serre and Bowman, {Natalie M.} and Viviana Simon and Richardson, {Lynne D.} and Russell Mcbride and Florian Krammer and Meenakshi Rana and Joshua Kennedy and Karl Boehme and Craig Forrest and Granger, {Steve W.} and Heaney, {Christopher D.} and {Knight Lapinski}, Maria and Shannon Wallet and Baric, {Ralph S.} and Luca Schifanella and Marcos Lopez and Soledad Fernandez and Eben Kenah and Panchal, {Ashish R.} and Britt, {William J.} and I{\~n}aki Sanz and Madhav Dhodapkar and Rafi Ahmed and Bartelt, {Luther A.} and Markmann, {Alena J.} and Lin, {Jessica T.} and Hagan, {Robert S.} and Wolfgang, {Matthew C.} and Jacek Skarbinski",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2022",

month = jun,

day = "1",

doi = "10.1093/ofid/ofac171",

language = "English (US)",

volume = "9",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies

AU - Figueiredo, Jane C.

AU - Hirsch, Fred R.

AU - Kushi, Lawrence H.

AU - Nembhard, Wendy N.

AU - Crawford, James M.

AU - Mantis, Nicholas

AU - Finster, Laurel

AU - Merin, Noah M.

AU - Merchant, Akil

AU - Reckamp, Karen L.

AU - Melmed, Gil Y.

AU - Braun, Jonathan

AU - Mcgovern, Dermot

AU - Parekh, Samir

AU - Corley, Douglas A.

AU - Zohoori, Namvar

AU - Amick, Benjamin C.

AU - Du, Ruofei

AU - Gregersen, Peter K.

AU - Diamond, Betty

AU - Taioli, Emanuela

AU - Sariol, Carlos

AU - Espino, Ana

AU - Weiskopf, Daniela

AU - Gifoni, Alba

AU - Brien, James

AU - Hanege, William

AU - Lipsitch, Marc

AU - Zidar, David A.

AU - Scheck Mcalearney, Ann

AU - Wajnberg, Ania

AU - Labaer, Joshua

AU - Yvonne Lewis, E.

AU - Binder, Raquel A.

AU - Moormann, Ann M.

AU - Forconi, Catherine

AU - Forrester, Sarah

AU - Batista, Jennifer

AU - Schieffelin, John

AU - Kim, Dongjoo

AU - Biancon, Giulia

AU - Vanoudenhove, Jennifer

AU - Halene, Stephanie

AU - Fan, Rong

AU - Barouch, Dan H.

AU - Alter, Galit

AU - Pinninti, Swetha

AU - Boppana, Suresh B.

AU - Pati, Sunil K.

AU - Latting, Misty

AU - Karaba, Andrew H.

AU - Roback, John

AU - Sekaly, Rafick

AU - Neish, Andrew

AU - Brincks, Ahnalee M.

AU - Granger, Douglas A.

AU - Karger, Amy B.

AU - Thyagarajan, Bharat

AU - Thomas, Stefani N.

AU - Klein, Sabra L.

AU - Cox, Andrea L.

AU - Lucas, Todd

AU - Furr-Holden, Debra

AU - Key, Kent

AU - Jones, Nicole

AU - Wrammerr, Jens

AU - Suthar, Mehul

AU - Yu Wong, Serre

AU - Bowman, Natalie M.

AU - Simon, Viviana

AU - Richardson, Lynne D.

AU - Mcbride, Russell

AU - Krammer, Florian

AU - Rana, Meenakshi

AU - Kennedy, Joshua

AU - Boehme, Karl

AU - Forrest, Craig

AU - Granger, Steve W.

AU - Heaney, Christopher D.

AU - Knight Lapinski, Maria

AU - Wallet, Shannon

AU - Baric, Ralph S.

AU - Schifanella, Luca

AU - Lopez, Marcos

AU - Fernandez, Soledad

AU - Kenah, Eben

AU - Panchal, Ashish R.

AU - Britt, William J.

AU - Sanz, Iñaki

AU - Dhodapkar, Madhav

AU - Ahmed, Rafi

AU - Bartelt, Luther A.

AU - Markmann, Alena J.

AU - Lin, Jessica T.

AU - Hagan, Robert S.

AU - Wolfgang, Matthew C.

AU - Skarbinski, Jacek

PY - 2022/6/1

Y1 - 2022/6/1

N2 - Background: Global efforts are needed to elucidate the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the underlying cause of coronavirus disease 2019 (COVID-19), including seroprevalence, risk factors, and long-Term sequelae, as well as immune responses after vaccination across populations and the social dimensions of prevention and treatment strategies. Methods: In the United States, the National Cancer Institute in partnership with the National Institute of Allergy and Infectious Diseases, established the SARS-CoV-2 Serological Sciences Network (SeroNet) as the nation's largest coordinated effort to study coronavirus disease 2019. The network comprises multidisciplinary researchers bridging gaps and fostering collaborations among immunologists, epidemiologists, virologists, clinicians and clinical laboratories, social and behavioral scientists, policymakers, data scientists, and community members. In total, 49 institutions form the SeroNet consortium to study individuals with cancer, autoimmune disease, inflammatory bowel diseases, cardiovascular diseases, human immunodeficiency virus, transplant recipients, as well as otherwise healthy pregnant women, children, college students, and high-risk occupational workers (including healthcare workers and first responders). Results: Several studies focus on underrepresented populations, including ethnic minorities and rural communities. To support integrative data analyses across SeroNet studies, efforts are underway to define common data elements for standardized serology measurements, cellular and molecular assays, self-reported data, treatment, and clinical outcomes. Conclusions: In this paper, we discuss the overarching framework for SeroNet epidemiology studies, critical research questions under investigation, and data accessibility for the worldwide scientific community. Lessons learned will help inform preparedness and responsiveness to future emerging diseases.

AB - Background: Global efforts are needed to elucidate the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the underlying cause of coronavirus disease 2019 (COVID-19), including seroprevalence, risk factors, and long-Term sequelae, as well as immune responses after vaccination across populations and the social dimensions of prevention and treatment strategies. Methods: In the United States, the National Cancer Institute in partnership with the National Institute of Allergy and Infectious Diseases, established the SARS-CoV-2 Serological Sciences Network (SeroNet) as the nation's largest coordinated effort to study coronavirus disease 2019. The network comprises multidisciplinary researchers bridging gaps and fostering collaborations among immunologists, epidemiologists, virologists, clinicians and clinical laboratories, social and behavioral scientists, policymakers, data scientists, and community members. In total, 49 institutions form the SeroNet consortium to study individuals with cancer, autoimmune disease, inflammatory bowel diseases, cardiovascular diseases, human immunodeficiency virus, transplant recipients, as well as otherwise healthy pregnant women, children, college students, and high-risk occupational workers (including healthcare workers and first responders). Results: Several studies focus on underrepresented populations, including ethnic minorities and rural communities. To support integrative data analyses across SeroNet studies, efforts are underway to define common data elements for standardized serology measurements, cellular and molecular assays, self-reported data, treatment, and clinical outcomes. Conclusions: In this paper, we discuss the overarching framework for SeroNet epidemiology studies, critical research questions under investigation, and data accessibility for the worldwide scientific community. Lessons learned will help inform preparedness and responsiveness to future emerging diseases.

KW - Cohort

KW - Covid-19

KW - Epidemiology

KW - Sars-cov-2

KW - Seronet

KW - Serosurveillance

UR - http://www.scopus.com/inward/record.url?scp=85133557503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85133557503&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofac171

DO - 10.1093/ofid/ofac171

M3 - Article

AN - SCOPUS:85133557503

SN - 2328-8957

VL - 9

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 6

M1 - ofac171

ER -

Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this